This RFA is soliciting applications proposing Phase 2 placebo-controlled, clinical trials to determine the safety and efficacy of monoclonal antibody therapies directed against amyloid-beta compared to placebo in diverse "mixed dementia" populations with a focus on Lewy Body Dementias (LBD). In this NOFO the mixed-etiology dementias (MED) that are of interest and that are in scope are cognitive impairment and dementia cases positive for 1) canonical Alzheimer’s pathology biomarkers (for example, amyloid-beta deposition assessed using positron emission tomography and/or low cerebrospinal fluid amyloid-beta 42 combined with elevated phosphorylated tau; and 2) a clinical LBD diagnosis, i.e. Parkinson’s disease dementia (PDD) and/or dementia with Lewy bodies (DLB).
Deadlines:
RFA-NS-25-010 Expiration Date January 25, 2025
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Jan 24, 2025
$46,900,000
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.